Methods for preparing purified polypeptide compositions
First Claim
Patent Images
1. A pharmaceutically acceptable composition comprising:
- a peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof comprising an alpha-helix and a cross-linker connecting a first amino acid and a second amino acid, the cross-linker spanning from 1 turn to 5 turns of the alpha-helix; and
a metal residue, from a metathesis catalyst, at a concentration of from about 0.5 ppm to about 10 ppm by weight as measured by nuclear inductively coupled plasma analysis (ICP) or nuclear inductively coupled plasma mass spectrometry analysis (ICP-ms);
wherein the pharmaceutically acceptable composition is suitable for administration to a human subject,and wherein the peptidomimetic macrocycle or the pharmaceutically acceptable salt is of Formula (I);
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
-
Citations
39 Claims
-
1. A pharmaceutically acceptable composition comprising:
-
a peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof comprising an alpha-helix and a cross-linker connecting a first amino acid and a second amino acid, the cross-linker spanning from 1 turn to 5 turns of the alpha-helix; and a metal residue, from a metathesis catalyst, at a concentration of from about 0.5 ppm to about 10 ppm by weight as measured by nuclear inductively coupled plasma analysis (ICP) or nuclear inductively coupled plasma mass spectrometry analysis (ICP-ms); wherein the pharmaceutically acceptable composition is suitable for administration to a human subject, and wherein the peptidomimetic macrocycle or the pharmaceutically acceptable salt is of Formula (I); - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 37, 38)
-
-
21. A pharmaceutically acceptable composition comprising:
-
a peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof comprising an alpha-helix and a cross-linker connecting a first amino acid and a second amino acid, the cross-linker spanning from 1 turn to 5 turns of the alpha-helix; and a metal residue comprising ruthenium, from a metathesis catalyst, at a concentration of below 10 ppm by weight as measured by nuclear inductively coupled plasma analysis (ICP) or nuclear inductively coupled plasma mass spectrometry analysis (ICP-ms); wherein the pharmaceutically acceptable composition is suitable for administration to a human subject, and wherein the peptidomimetic macrocycle or the pharmaceutically acceptable salt is of Formula (I); - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 39)
-
Specification